Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II study
- 1 December 2001
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 34, 31-35
- https://doi.org/10.1016/s0169-5002(01)00402-0
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapyLung Cancer, 1999
- Second-Line Chemotherapy with 96-Hour Infusional Paclitaxel in Refractory Non-Small Cell Lung Cancer: Report of a Phase II TrialCancer Investigation, 1999
- Where to go with new expensive treatments in NSCLCBritish Journal of Cancer, 1998
- 156 Phase II study of docetaxel (Taxotere®) in 1st and 2nd line NSCLCLung Cancer, 1997
- 72 Multicenter trial of docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): Confirmation of prolonged survivalLung Cancer, 1997
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancerCancer, 1995
- Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancerBritish Journal of Cancer, 1995
- Polychemotherapy in advanced non small cell lung cancer: a meta-analysisThe Lancet, 1993
- Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancerBritish Journal of Cancer, 1989